The presence of increased or densely clustered TIL or expression of PD-L1/PD-1 immune checkpoint molecules is usually associated with a better prognosis, increased tumor immunity, and identifies potential candidates for immune checkpoint blockade therapy [151,153,157,158,159]. The gene discussed is PDCD1; the disease is neoplasm.